Fosun Pharma Announces 2021 Interim Results, Innovation Results Continue to Land, International Operation Capability Further Improved

Performance highlights:

· Achieved operating income of 16.

· Achieved a net profit of 2.

· Achieve a net profit attributable to shareholders of listed companies deducting non-recurring gains and losses of 1.

· R&D expenses were 1.

· The joint venture Fosun Kate’s Yi Kai Da is the first CAR-T cell therapy product approved for marketing in China;

· Fubitai® (mRNA Covid-19 vaccine, BNT162b2) was included in the government vaccination program in Hong Kong and Macau in the first half of the year; and it plans to supply 15 million doses of mRNA Covid-19 vaccine to Taiwan, China

On August 23, 2021, Shanghai Fosun Pharmaceutical (Group) Co.

In the first half of 2021, Fosun Pharma adhered to the "4IN" strategy and achieved steady growth in overall performance

Innovative achievements continue to land The first domestic CAR-T cell therapy product was approved for listing

Fosun Pharma continues to be oriented towards innovation and internationalization, increasing R&D investment, and accelerating new drug development and clinical capacity building through independent R&D, cooperative development, license introduction, in-depth incubation and other diversified and multi-level cooperation modes, and connecting with global outstanding scientists The team, leading technology and high-value products, and relying on the overall management of innovative R&D projects by the global R&D center, promote the development and transformation of innovative technologies and products

During the reporting period, Fosun Pharma’s R&D investment was 1.

In June 2021, the joint venture Fosun Kate’s Yikai Dacheng is the first CAR-T cell therapy product approved for marketing in China, which is mainly used to treat relapsed or refractory large B cells after receiving second-line or above systemic treatment.

In the first half of 2021, Fubitai® (mRNA new crown vaccine, namely BNT162b2) will be included in the government vaccination program in Hong Kong and Macau

Stable growth of core pharmaceutical business, launch of innovative products to promote product structure optimization

During the reporting period, the core pharmaceutical business revenue maintained steady growth and the product structure continued to be optimized

Fosun Pharma is committed to promoting innovative research and development, and is oriented towards meeting unmet clinical needs and improving the availability of medicines, accelerating the implementation of innovative technologies and products

During the reporting period, the sales volume of self-developed product Han Likang (rituximab injection) increased significantly.

The preliminary integration of diagnosis and medical aesthetics business with improved quality and efficiency has been completed

During the reporting period, Fosun Pharma's medical device business has initially formed three major business branches with the core of medical beauty, respiratory health, and professional medical care

In the first half of 2021, the diagnostics sector will actively promote strategic upgrades and internal integration

Internationalized operation capabilities further enhance the proportion of overseas revenue to exceed 30%

In the first half of 2021, Fosun Pharma will implement its internationalization strategy in multiple dimensions including innovative R&D, BD, production and operation, and commercialization.
The global BD team will be deployed in frontier areas through cooperative development and license introduction.
The United States, Africa, Europe and India The drug clinical and registration team continued to strengthen overseas drug registration and reporting capabilities, domestic production lines accelerated the promotion of international quality system certification, international marketing deepened capacity building, and continued to expand the international market
.
During the reporting period, Fosun Pharma achieved operating income of 5.
198 billion yuan in regions outside of Mainland China and other countries, accounting for 30.
66% of the overall revenue
.

Fosun Pharma already has a mature sales network and upstream and downstream customer resources in the English and French-speaking regions of sub-Saharan Africa
.
After years of hard work, the holding subsidiary Gland Pharma has become one of the largest and fastest-growing companies in India focusing on the production of injections, with operations in 60 countries
.

Looking forward to the future, Wu Yifang, Chairman and CEO of Fosun Pharma, said: “In the second half of 2021, the development challenges and opportunities of the entire pharmaceutical industry
will coexist .
Fosun Pharma will strive to optimize product strategies, improve R&D efficiency, and continue to innovate and internationalize.
As a guide, strengthen globalization construction, enhance innovative research and development capabilities, international drug registration and application capabilities, vigorously develop strategic products, and actively seek opportunities for industry mergers and acquisitions and integration, build and promote the integration and coordination of product lines and supply chains, and achieve Revenue and profit continue to grow
.
At the same time, continue to optimize the operational efficiency of the medical service business, accelerate the construction of advantageous disciplines, strengthen quality management, accelerate the Internet transformation of the health industry, and further promote breakthroughs in the consumer medical field, expand the scale of operations, and improve operational management and Internationalization capabilities
.
"